How to Export Cannabis as a U.S. Weed Brand: The 60-Day DEA Registration Window Explained

A major shift in U.S. cannabis policy is creating one of the biggest international business opportunities the legal industry has seen to date.

Following the April 2026 final order from the U.S. Department of Justice (DOJ), the Drug Enforcement Administration (DEA) officially moved FDA-approved marijuana drugs and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act.

For the first time, DEA-registered cannabis operators may now apply for permits to import and export approved medical marijuana products internationally.

While the headlines around Schedule III have largely focused on IRS 280E tax relief, a much bigger long-term story is beginning to emerge: federally recognized export pathways for American cannabis companies. And the clock is already ticking.

Need help navigating the system? Contact us at high@grnroom.com and our team can connect you with regulatory and compliance specialists experienced in navigating this evolving landscape.

The 60-Day DEA Registration Window Explained

The DEA has created an expedited federal registration pathway for existing state-licensed medical marijuana operators. Businesses that apply within 60 days of the Federal Register publication — effectively by June 27, 2026 — are eligible for priority processing.

According to the DEA framework:

• Early applicants may continue operating under existing state medical licenses while federal registration is pending
• The DEA is targeting a six-month review period for expedited applications
• Registered operators may become eligible to participate in federally permitted import and export activity involving approved medical marijuana products
• The changes apply specifically to medical cannabis operations, not adult-use businesses

For many operators, this represents the first realistic opportunity to begin positioning themselves for international cannabis trade from the United States.

A major shift in U.S. cannabis policy is creating one of the biggest international business opportunities the legal industry has seen to date.

Following the April 2026 final order from the U.S. Department of Justice (DOJ), the Drug Enforcement Administration (DEA) officially moved FDA-approved marijuana drugs and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act.

For the first time, DEA-registered cannabis operators may now apply for permits to import and export approved medical marijuana products internationally.

While the headlines around Schedule III have largely focused on IRS 280E tax relief, a much bigger long-term story is beginning to emerge: federally recognized export pathways for American cannabis companies. And the clock is already ticking.

Need help navigating the system? Contact us at high@grnroom.com and our team can connect you with regulatory and compliance specialists experienced in navigating this evolving landscape.

The 60-Day DEA Registration Window Explained

The DEA has created an expedited federal registration pathway for existing state-licensed medical marijuana operators. Businesses that apply within 60 days of the Federal Register publication — effectively by June 27, 2026 — are eligible for priority processing.

According to the DEA framework:

• Early applicants may continue operating under existing state medical licenses while federal registration is pending
• The DEA is targeting a six-month review period for expedited applications
• Registered operators may become eligible to participate in federally permitted import and export activity involving approved medical marijuana products
• The changes apply specifically to medical cannabis operations, not adult-use businesses

For many operators, this represents the first realistic opportunity to begin positioning themselves for international cannabis trade from the United States.

Why Cannabis Brands Are Suddenly Paying Attention to Exports

The global medical cannabis market is expanding rapidly.

Countries across Europe, Latin America, Australia, and parts of Asia continue building regulated medical programs, while demand for GMP-certified cannabis products, genetics, extracts, and formulations grows year over year.

Historically, Canadian companies dominated global exports because federal legality gave them access to international treaties and export permits.

The United States largely sat on the sidelines.

That dynamic may now begin to change.

If DEA registration approvals move forward as expected, U.S. medical cannabis companies could gain a pathway into international supply chains that were previously inaccessible.

For sophisticated operators in states like California, Florida, New York, Illinois, Michigan, Arizona, and Pennsylvania, the implications are massive:

• International licensing deals
• Cross-border medical cannabis partnerships
• Export opportunities into emerging markets
• Increased enterprise valuations
• Potential pharmaceutical and clinical pathways
• Access to federally compliant infrastructure

This is particularly important for multi-state operators and advanced medical operators already operating at pharmaceutical-grade production standards.

Schedule III Does Not Mean Recreational Cannabis Exports

One of the biggest misconceptions surrounding the DEA rescheduling announcement is that all cannabis is now federally recognized.

That is not the case.

The current framework specifically applies to:

• FDA-approved marijuana products
• State-licensed medical marijuana operators

Adult-use cannabis remains federally prohibited under Schedule I.

That means recreational cannabis companies cannot simply begin shipping products internationally.

However, many vertically integrated operators already have medical infrastructure in place or may now begin exploring medical pathways more aggressively because of the export potential.

DEA Export Permits Are Not Automatic

Another critical detail: Schedule III does not create blanket export authorization.

Every import or export transaction still requires DEA permitting and oversight.

Operators will need to navigate:

• DEA registration requirements
• Federal security standards
• Supply chain documentation
• Controlled substance tracking
• International treaty compliance
• State-by-state medical regulations
• Country-specific import rules

The process is highly regulated and operationally intensive.

According to DEA guidance, applicants must also demonstrate formal Standard Operating Procedures (SOPs) covering areas like inventory management, security, storage, destruction, theft reporting, and controlled substance handling.

The International Cannabis Race Is Accelerating

This development comes at a time when global cannabis competition is intensifying.

Canadian licensed producers have spent years building export infrastructure and international relationships. European pharmaceutical cannabis standards continue evolving rapidly. Countries like Germany, Australia, Portugal, Israel, Colombia, and Thailand remain major focal points for international cannabis trade discussions.

Now, American operators may finally have a legitimate pathway into that ecosystem.

The companies that move first during this DEA registration window could gain a significant advantage over operators that wait for additional clarity.

Because once international supply relationships are established, they become increasingly difficult to displace.

What Cannabis Operators Should Be Doing Right Now

For medical cannabis operators considering DEA registration and future export capabilities, the immediate priority is preparation.

That includes:

• Reviewing eligibility for DEA registration
• Auditing SOPs and compliance systems
• Evaluating facility security standards
• Assessing international market opportunities
• Understanding import/export treaty requirements
• Building legal and regulatory infrastructure
• Identifying strategic global partners

Many cannabis companies are realizing they need specialized regulatory guidance quickly — especially before the expedited application window closes.

A Potential Turning Point for the U.S. Cannabis Industry

For years, American cannabis operators have existed in a strange middle ground: building billion-dollar businesses without access to federal recognition or global commerce.

The DEA’s Schedule III framework may not fully solve that problem yet, but it could mark the beginning of a very different era.

One where federally recognized medical cannabis businesses in the United States begin participating in legitimate international cannabis trade for the first time.

And with a 60-day expedited registration window already underway, many operators are now racing to position themselves before the next wave of federal policy changes arrives.

Looking to Explore DEA Registration or International Cannabis Export Opportunities?

If your company is evaluating DEA registration, medical cannabis export opportunities, or international expansion strategies, contact us at high@grnroom.com and our team can connect you with regulatory and compliance specialists experienced in navigating this evolving landscape.

From branding and go-to-market strategy to international cannabis business development and regulatory guidance, we’re actively helping operators prepare for the next phase of the global cannabis industry.